Even the association of CYP2C19 polymorphisms with platelet responsiveness to Clopidogrel was largely approved among ACS/PCI patients, the association among patients under Clopidogrel for other indications (e.g. stable angina and arterial fibrillation), have been declared negative [33, 34]. This evidence concerns the gene CYP2C19 and angina pectoris.